|
🐜
|
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
14 auth.
S. Shernan,
J. Fitch,
N. Nussmeier,
John C. Chen,
S. Rollins,
C. Mojcik,
K. Malloy,
Thomas G. Todaro,
T. Filloon,
S. Boyce,
...
D. M. Gangahar,
Michael Goldberg,
L. Saidman,
D. Mangano
|
6 |
2004 |
6
🐜
|
